COMPANY

Variantyx provides advanced genomic diagnostics services to clinicians and hospitals around the world.

The genomic diagnostics industry is currently at an inflection point, shifting from traditional technologies to Whole Genome / Whole Exome (“WGS/WES”) Next Generation Sequencing (“NGS”).

The barrier to entry for WGS/WES diagnostics is high.

  • WGS/WES based diagnostics is a complex and labor intensive process in its infancy. Today, each case is expensive and time consuming, requiring many hours of work from highly skilled professionals.
  • Purchasing and operating an NGS sequencing core is both difficult and costly.

These factors make it impractical for the vast majority of hospitals to conduct such tests on an in-house basis. However, outsourcing the tests to third party genomic centers distances the patients from the diagnosticians, thereby reducing the quality of the diagnosis while incurring higher charges.

Variantyx is pioneering a paradigm shift in genomic diagnostics with our Genomic Intelligence® platform:

  • Our highly automated WGS/WES diagnostics platform significantly lowers the time taken to diagnose a case, reducing both the cost and turnaround time.
  • Our service is integrated with a global network of world-leading sequencing partners. This enables clinical centers to carry out the complete WES/WGS diagnosis in-house, from sample collection to clinical report, without disconnecting the diagnosing physician from the patient and without the need to build and maintain an NGS core facility.
  • The result is the best of both worlds; high quality diagnosis at reduced cost and with a rapid turnaround time.

Since launching our service to select industry thought-leaders in the third quarter of 2015, we have processed more than 1,000 samples for a significant number of hospitals. Our unparalleled diagnostic results have positioned Variantyx as an industry leader for genomic diagnosis within the clinical community.

Variantyx Inc., headquartered in Boston Massachusetts, was founded in early 2014. Our interdisciplinary team has extensive expertise in executive management, medicine, research, engineering, information technology, wet-bench, and service operations. We are committed to our customers’ success and the advancement of clinical genomics.

Meet The Team

Haim

Haim Neerman

CEO


> Full Bio

Haim's career spans over 20 years of technology entrepreneurship. Prior to co-founding Variantyx, Haim cofounded Credorax Inc. – a global credit card acquiring bank , Fabrix systems (acquired by Ericson), Bandwiz Inc. and Actil Ltd. Haim is a physics, math and computer science graduate of the Talpiot program / Hebrew university of Jerusalem

Gregory Faust

Gregory Faust
PhD

CTO


> Full Bio

After receiving a MS in computer science from MIT, Greg has managed many software product development projects from the ground up, including product management, software development, quality assurance and documentation. He has held executive positions at Microsoft and two successful software start-up companies. Greg joined Variantyx after completing an interdisciplinary PhD in Bioinformatics from the University of Virginia where his research focused on the development of novel genomic analysis algorithms.

Tomer Jackman

Tomer Jackman

COO


> Full Bio

Tomer serves as the Chief Operating Officer of Variantyx and is responsible for delivering services to customers. This includes day to day operations such as supply chain management, customer care, and above all, productivity. Prior to co-founding Variantyx, Tomer was responsible for hardware development operations in Pivotal/Greenplum division of EMC2 where he helped develop server clusters for "Massive Parallel Processing" databases. This followed a decade with EMC2 in several hardware engineering roles, and work in R&D with HP/Indigo. He holds a high-tech MBA from Northeastern University in Boston, and a BSc in Electrical Engineering from Tel-Aviv University.

0

Muthu Meyyappan
PhD

CCO


> Full Bio

Muthu serves as the Chief Commercial Officer and is responsible for the overall commercial strategy including sales, marketing and customer support. His primary focus is to drive market adoption of Variantyx’s products and services and to drive revenue growth. Prior to joining Variantyx, Muthu was the Vice President of Advanced Genomics Commercial Operations for QIAGEN where he was responsible for worldwide revenue for the bioinformatics franchise. He has more than 17+ years’ experience in customer facing environments within the pharmaceutical, biotech, academic research and clinical sectors where he represented Incyte Genomics and was the Chief Business Officer for BIOBASE Corporation. Muthu holds a Bachelor’s degree in Biotechnology from the Rochester Institute of Technology, New York and a PhD in Cancer Biology from the Southern Alberta Cancer Research Center, in Calgary, Canada.

> Full Bio

Haim's career spans over 20 years of technology entrepreneurship. Prior to co-founding Variantyx, Haim cofounded Credorax Inc. – a global credit card acquiring bank , Fabrix systems (acquired by Ericson), Bandwiz Inc. and Actil Ltd. Haim is a physics, math and computer science graduate of the Talpiot program / Hebrew university of Jerusalem

    
 >Full Bio

After receiving a MS in computer science from MIT, Greg has managed many software product development projects from the ground up, including product management, software development, quality assurance and documentation. He has held executive positions at Microsoft and two successful software start-up companies. Greg joined Variantyx after completing an interdisciplinary PhD in Bioinformatics from the University of Virginia where his research focused on the development of novel genomic analysis algorithms.

        >Full Bio

Tomer serves as the Chief Operating Officer of Variantyx and is responsible for delivering services to customers. This includes day to day operations such as supply chain management, customer care, and above all, productivity. Prior to co-founding Variantyx, Tomer was responsible for hardware development operations in Pivotal/Greenplum division of EMC2 where he helped develop server clusters for "Massive Parallel Processing" databases. This followed a decade with EMC2 in several hardware engineering roles, and work in R&D with HP/Indigo. He holds a high-tech MBA from Northeastern University in Boston, and a BSc in Electrical Engineering from Tel-Aviv University.

        >Full Bio

Muthu serves as the Chief Commercial Officer and is responsible for the overall commercial strategy including sales, marketing and customer support. His primary focus is to drive market adoption of Variantyx’s products and services and to drive revenue growth. Prior to joining Variantyx, Muthu was the Vice President of Advanced Genomics Commercial Operations for QIAGEN where he was responsible for worldwide revenue for the bioinformatics franchise. He has more than 17+ years’ experience in customer facing environments within the pharmaceutical, biotech, academic research and clinical sectors where he represented Incyte Genomics and was the Chief Business Officer for BIOBASE Corporation. Muthu holds a Bachelor’s degree in Biotechnology from the Rochester Institute of Technology, New York and a PhD in Cancer Biology from the Southern Alberta Cancer Research Center, in Calgary, Canada.

> Full Bio

Haim's career spans over 20 years of technology entrepreneurship. Prior to co-founding Variantyx, Haim cofounded Credorax Inc. – a global credit card acquiring bank , Fabrix systems (acquired by Ericson), Bandwiz Inc. and Actil Ltd. Haim is a physics, math and computer science graduate of the Talpiot program / Hebrew university of Jerusalem

> Full Bio

After receiving a MS in computer science from MIT, Greg has managed many software product development projects from the ground up, including product management, software development, quality assurance and documentation. He has held executive positions at Microsoft and two successful software start-up companies. Greg joined Variantyx after completing an interdisciplinary PhD in Bioinformatics from the University of Virginia where his research focused on the development of novel genomic analysis algorithms.

> FullBio

Tomer serves as the Chief Operating Officer of Variantyx and is responsible for delivering services to customers. This includes day to day operations such as supply chain management, customer care, and above all, productivity. Prior to co-founding Variantyx, Tomer was responsible for hardware development operations in Pivotal/Greenplum division of EMC2 where he helped develop server clusters for "Massive Parallel Processing" databases. This followed a decade with EMC2 in several hardware engineering roles, and work in R&D with HP/Indigo. He holds a high-tech MBA from Northeastern University in Boston, and a BSc in Electrical Engineering from Tel-Aviv University.

      > Full Bio

Muthu serves as the Chief Commercial Officer and is responsible for the overall commercial strategy including sales, marketing and customer support. His primary focus is to drive market adoption of Variantyx’s products and services and to drive revenue growth. Prior to joining Variantyx, Muthu was the Vice President of Advanced Genomics Commercial Operations for QIAGEN where he was responsible for worldwide revenue for the bioinformatics franchise. He has more than 17+ years’ experience in customer facing environments within the pharmaceutical, biotech, academic research and clinical sectors where he represented Incyte Genomics and was the Chief Business Officer for BIOBASE Corporation. Muthu holds a Bachelor’s degree in Biotechnology from the Rochester Institute of Technology, New York and a PhD in Cancer Biology from the Southern Alberta Cancer Research Center, in Calgary, Canada.

Yaron Rachmany

Yaron Rachmany

CIO



> Full Bio

Yaron Rachmany oversees Variantyx’ IT system and Business processes. Prior to joining Variantyx, Yaron served as Director of Systems Operations and as a Director of IT Applications at Semtech Corporation (NASDAQ: SMTC). Prior to Semtech Yaron held the VP of Information systems position with Credorax. Prior to Credorax, Yaron held senior Information Systems positions with Microsemi MSCC (NASDAQ, Intel INTC (NASDAQ) and ECI Telecom.

Yaron holds a M.Sc. and a B.Sc. in industrial engineering and Management (specialized in Information Systems) from Ben Gurion University in Israel.

Allan J Fisher

Allan J. Fisher
MD,FACOG,FACMG

Medical Director



> Full Bio

Allan J Fisher, MD graduated his professional studies at St. Louis University School of Medicine, St. Louis, Missouri. He proceeded to complete his postgraduate work at Emory University Affiliated Hospitals in Atlanta, Georgia, for his Gynecology and Obstetrics residency, Maternal Fetal Medicine Fellowship, and Medical Genetics Fellowship, which he is Boarded for all three. His experiences include many years of academic and clinical medicine, mostly in the Northeast. Leadership roles of Directorships for Maternal Fetal Medicine and Perinatal / Reproductive Genetics and Medical Director as well as Chairs to multiple Volunteer Organizations. He has over 25 years experience of teaching students, residents, and fellows and has published multiple articles and chapters. He is a member to many outside Professional and Medical organizations and Boards, including two State Medical Boards. He has close to 20 years experience as an active volunteer member to the March of Dimes, New Jersey Chapter, and was presented the Franklin Award due to his activism in launching the preterm delivery campaign in New Jersey.

His primary medical interests include Prenatal Genetics and Diagnosis, Fetal Dysmorphology, Genetic Screening, Ultrasound (3D/4D, Fetal Echocardiography, Detailed Cranial Sonography). Most recent publications include the uses of Microarrays in Prenatal Diagnosis involving the largest cohort studied of over 5000 fetuses. His primary outside interests are photography, fly fishing and his family.

NaomiMeeks

Naomi Meeks
MD, FAAP, FACMG

Lab Director


> Full Bio

Naomi attended medical school at the University of Iowa Carver College of Medicine and completed a Pediatrics residency at Indiana University School of Medicine/Riley Hospital for Children.  After residency, Naomi received training in Clinical Genetics and Molecular Genetics at the University of Colorado and is board certified in Pediatrics, Clinical Genetics & Molecular Genetics.  Naomi’s clinical practice has included Pediatric Genetics with specialty interests including 22q11.2 Deletion Syndrome and Differences of Sexual Development.  Naomi also serves as a medical director for the Children's Hospital Colorado Molecular Genetics Laboratory and is involved in teaching and research.

JenniferHogan

Jennifer Hogan

VP of Marketing


> Full Bio

Jennifer serves as the VP of Marketing and is responsible for content strategy and tactical execution driving awareness, education and lead generation for Variantyx’s products and services. Prior to joining Variantyx, Jennifer led product management and product marketing for the genetic disease portfolio within QIAGEN’s bioinformatics business area. She has many years of experience leading customer-focused product development of biological databases and software at QIAGEN, BIOBASE Corporation and Incyte Genomics. Jennifer received her PhD in Biochemistry and Molecular Biology from the University of New Hampshire studying developmental genetics in a model organism system. 

> Full Bio

Yaron Rachmany oversees Variantyx’ IT system and Business processes. Prior to joining Variantyx, Yaron served as Director of Systems Operations and as a Director of IT Applications at Semtech Corporation (NASDAQ: SMTC). Prior to Semtech Yaron held the VP of Information systems position with Credorax. Prior to Credorax, Yaron held senior Information Systems positions with Microsemi MSCC (NASDAQ, Intel INTC (NASDAQ) and ECI Telecom.

Yaron holds a M.Sc. and a B.Sc. in industrial engineering and Management (specialized in Information Systems) from Ben Gurion University in Israel.

   
  >Full Bio

Allan J Fisher, MD graduated his professional studies at St. Louis University School of Medicine, St. Louis, Missouri. He proceeded to complete his postgraduate work at Emory University Affiliated Hospitals in Atlanta, Georgia, for his Gynecology and Obstetrics residency, Maternal Fetal Medicine Fellowship, and Medical Genetics Fellowship, which he is Boarded for all three. His experiences include many years of academic and clinical medicine, mostly in the Northeast. Leadership roles of Directorships for Maternal Fetal Medicine and Perinatal / Reproductive Genetics and Medical Director as well as Chairs to multiple Volunteer Organizations. He has over 25 years experience of teaching students, residents, and fellows and has published multiple articles and chapters. He is a member to many outside Professional and Medical organizations and Boards, including two State Medical Boards. He has close to 20 years experience as an active volunteer member to the March of Dimes, New Jersey Chapter, and was presented the Franklin Award due to his activism in launching the preterm delivery campaign in New Jersey.

His primary medical interests include Prenatal Genetics and Diagnosis, Fetal Dysmorphology, Genetic Screening, Ultrasound (3D/4D, Fetal Echocardiography, Detailed Cranial Sonography). Most recent publications include the uses of Microarrays in Prenatal Diagnosis involving the largest cohort studied of over 5000 fetuses. His primary outside interests are photography, fly fishing and his family.

        >Full Bio

Naomi attended medical school at the University of Iowa Carver College of Medicine and completed a Pediatrics residency at Indiana University School of Medicine/Riley Hospital for Children.  After residency, Naomi received training in Clinical Genetics and Molecular Genetics at the University of Colorado and is board certified in Pediatrics, Clinical Genetics & Molecular Genetics.  Naomi’s clinical practice has included Pediatric Genetics with specialty interests including 22q11.2 Deletion Syndrome and Differences of Sexual Development.  Naomi also serves as a medical director for the Children's Hospital Colorado Molecular Genetics Laboratory and is involved in teaching and research.

        >Full Bio

Jennifer serves as the VP of Marketing and is responsible for content strategy and tactical execution driving awareness, education and lead generation for Variantyx’s products and services. Prior to joining Variantyx, Jennifer led product management and product marketing for the genetic disease portfolio within QIAGEN’s bioinformatics business area. She has many years of experience leading customer-focused product development of biological databases and software at QIAGEN, BIOBASE Corporation and Incyte Genomics. Jennifer received her PhD in Biochemistry and Molecular Biology from the University of New Hampshire studying developmental genetics in a model organism system. 

> Full bio

Yaron Rachmany oversees Variantyx’ IT system and Business processes. Prior to joining Variantyx, Yaron served as Director of Systems Operations and as a Director of IT Applications at Semtech Corporation (NASDAQ: SMTC). Prior to Semtech Yaron held the VP of Information systems position with Credorax. Prior to Credorax, Yaron held senior Information Systems positions with Microsemi MSCC (NASDAQ, Intel INTC (NASDAQ) and ECI Telecom.

Yaron holds a M.Sc. and a B.Sc. in industrial engineering and Management (specialized in Information Systems) from Ben Gurion University in Israel.


 

> Full Bio

Allan J Fisher, MD graduated his professional studies at St. Louis University School of Medicine, St. Louis, Missouri. He proceeded to complete his postgraduate work at Emory University Affiliated Hospitals in Atlanta, Georgia, for his Gynecology and Obstetrics residency, Maternal Fetal Medicine Fellowship, and Medical Genetics Fellowship, which he is Boarded for all three. His experiences include many years of academic and clinical medicine, mostly in the Northeast. Leadership roles of Directorships for Maternal Fetal Medicine and Perinatal / Reproductive Genetics and Medical Director as well as Chairs to multiple Volunteer Organizations. He has over 25 years experience of teaching students, residents, and fellows and has published multiple articles and chapters. He is a member to many outside Professional and Medical organizations and Boards, including two State Medical Boards. He has close to 20 years experience as an active volunteer member to the March of Dimes, New Jersey Chapter, and was presented the Franklin Award due to his activism in launching the preterm delivery campaign in New Jersey.

His primary medical interests include Prenatal Genetics and Diagnosis, Fetal Dysmorphology, Genetic Screening, Ultrasound (3D/4D, Fetal Echocardiography, Detailed Cranial Sonography). Most recent publications include the uses of Microarrays in Prenatal Diagnosis involving the largest cohort studied of over 5000 fetuses. His primary outside interests are photography, fly fishing and his family.

> Full Bio

Naomi attended medical school at the University of Iowa Carver College of Medicine and completed a Pediatrics residency at Indiana University School of Medicine/Riley Hospital for Children.  After residency, Naomi received training in Clinical Genetics and Molecular Genetics at the University of Colorado and is board certified in Pediatrics, Clinical Genetics & Molecular Genetics.  Naomi’s clinical practice has included Pediatric Genetics with specialty interests including 22q11.2 Deletion Syndrome and Differences of Sexual Development.  Naomi also serves as a medical director for the Children's Hospital Colorado Molecular Genetics Laboratory and is involved in teaching and research.

      > Full Bio

Jennifer serves as the VP of Marketing and is responsible for content strategy and tactical execution driving awareness, education and lead generation for Variantyx’s products and services. Prior to joining Variantyx, Jennifer led product management and product marketing for the genetic disease portfolio within QIAGEN’s bioinformatics business area. She has many years of experience leading customer-focused product development of biological databases and software at QIAGEN, BIOBASE Corporation and Incyte Genomics. Jennifer received her PhD in Biochemistry and Molecular Biology from the University of New Hampshire studying developmental genetics in a model organism system. 

Noam Shomron

Noam Shomron
PhD

CSO



> Full Bio

Dr Noam Shomron heads the Genomic Intelligence Research Laboratory at the Faculty of Medicine at Tel Aviv University. Dr Shomron leads a multidisciplinary team of scientists consisting of biologists, physicians, engineers, bioinformaticians and mathematicians. The team aims to deepen our understanding of the development of diseases in order to generate a significant impact through translating ideas into clinical reality.

Dr Shomron is also the Editor-in-Chief of ‘Genetics Research’ (Cambridge University Press); Director of Rare Genomics Israel a non-profit organization that assists children and families with undiagnosed genetic disorders; Academic Director of ScienceAbroad; and Co-founder of several Biotech companies.

Alexander Kaplun

Alexander Kaplun
PhD

Dir. Product Management

> Full Bio

Dr. Kaplun is among the developers of comprehensive pharmacogenomic database PGMD and other tools and databases aiming to satisfy the growing demand for clinical genomic analysis. He is an author of over 20 peer-reviewed publications.

Before joining Variantyx, Dr Kaplun served as Senior Scientist and Associate Manager of Advanced Genomics at QIAGEN Bioinformatics. During his postdoctoral training he was involved in identification of novel regulatory mechanisms of signal transduction in cancer, factors affecting metastasis and in investigation of longevity mechanisms at Karmanos Cancer Institute. He received his PhD summa cum laude from Ben-Gurion University of the Negev.

Shira Modai

Shira Modai
PhD

Dir. Clinical Operations

> Full Bio

Prior to joining Variantyx, Dr. Shira Modai managed the genomic center of Tel Aviv university. Shira holds a B.Sc in Biotechnology and Food engineering, an M.Sc. in Medical science specializing in Virology and Ph.D. in biology from Tel Aviv University focusing on miRNAs expressed from viral genomes and the interplay with host miRNAs and genes. The Ph.D. thesis was based on the first Next Generation Sequencing runs done in TAU Genomic lab utilizing the Illumina Genome Analyzer IIX sequencer. Shira’s responsibility with Variantyx includes communication with the clinical community (clinicians and hospitals) throughout the lifecycle of a test providing a single point of contact with Variantyx

> Full bio

Dr Noam Shomron heads the Genomic Intelligence Research Laboratory at the Faculty of Medicine at Tel Aviv University. Dr Shomron leads a multidisciplinary team of scientists consisting of biologists, physicians, engineers, bioinformaticians and mathematicians. The team aims to deepen our understanding of the development of diseases in order to generate a significant impact through translating ideas into clinical reality.

Dr Shomron is also the Editor-in-Chief of ‘Genetics Research’ (Cambridge University Press); Director of Rare Genomics Israel a non-profit organization that assists children and families with undiagnosed genetic disorders; Academic Director of ScienceAbroad; and Co-founder of several Biotech companies.

  
  >Full Bio

Dr. Kaplun is among the developers of comprehensive pharmacogenomic database PGMD and other tools and databases aiming to satisfy the growing demand for clinical genomic analysis. He is an author of over 20 peer-reviewed publications.

Before joining Variantyx, Dr Kaplun served as Senior Scientist and Associate Manager of Advanced Genomics at QIAGEN Bioinformatics. During his postdoctoral training he was involved in identification of novel regulatory mechanisms of signal transduction in cancer, factors affecting metastasis and in investigation of longevity mechanisms at Karmanos Cancer Institute. He received his PhD summa cum laude from Ben-Gurion University of the Negev.

        >Full Bio

Prior to joining Variantyx, Dr. Shira Modai managed the genomic center of Tel Aviv university. Shira holds a B.Sc in Biotechnology and Food engineering, an M.Sc. in Medical science specializing in Virology and Ph.D. in biology from Tel Aviv University focusing on miRNAs expressed from viral genomes and the interplay with host miRNAs and genes. The Ph.D. thesis was based on the first Next Generation Sequencing runs done in TAU Genomic lab utilizing the Illumina Genome Analyzer IIX sequencer. Shira’s responsibility with Variantyx includes communication with the clinical community (clinicians and hospitals) throughout the lifecycle of a test providing a single point of contact with Variantyx

> Full Bio

Dr Noam Shomron heads the Genomic Intelligence Research Laboratory at the Faculty of Medicine at Tel Aviv University. Dr Shomron leads a multidisciplinary team of scientists consisting of biologists, physicians, engineers, bioinformaticians and mathematicians. The team aims to deepen our understanding of the development of diseases in order to generate a significant impact through translating ideas into clinical reality.

Dr Shomron is also the Editor-in-Chief of ‘Genetics Research’ (Cambridge University Press); Director of Rare Genomics Israel a non-profit organization that assists children and families with undiagnosed genetic disorders; Academic Director of ScienceAbroad; and Co-founder of several Biotech companies.

> Full Bio

Dr. Kaplun is among the developers of comprehensive pharmacogenomic database PGMD and other tools and databases aiming to satisfy the growing demand for clinical genomic analysis. He is an author of over 20 peer-reviewed publications.

Before joining Variantyx, Dr Kaplun served as Senior Scientist and Associate Manager of Advanced Genomics at QIAGEN Bioinformatics. During his postdoctoral training he was involved in identification of novel regulatory mechanisms of signal transduction in cancer, factors affecting metastasis and in investigation of longevity mechanisms at Karmanos Cancer Institute. He received his PhD summa cum laude from Ben-Gurion University of the Negev.

> Full Bio

Prior to joining Variantyx, Dr. Shira Modai managed the genomic center of Tel Aviv university. Shira holds a B.Sc in Biotechnology and Food engineering, an M.Sc. in Medical science specializing in Virology and Ph.D. in biology from Tel Aviv University focusing on miRNAs expressed from viral genomes and the interplay with host miRNAs and genes. The Ph.D. thesis was based on the first Next Generation Sequencing runs done in TAU Genomic lab utilizing the Illumina Genome Analyzer IIX sequencer. Shira’s responsibility with Variantyx includes communication with the clinical community (clinicians and hospitals) throughout the lifecycle of a test providing a single point of contact with Variantyx.

   

Tab Content

Nir Pillar

Nir Pillar
MD

Clinical Advisor



> Full Bio

Dr. Nir Pillar, M.D., has experience at the Medical Oncology Department at Sheba Medical Center, Tel HaShomer, Israel. His current Ph.D. research focuses on exploring the deep mechanism of genetic based diseases and the combination of DNA and RNA changes that lead to their development. In his role as Variantyx' Clinical Adviser, he plans and implements novel algorithms for understanding the genetic origin of genetic changes that lead to severe phenotypes. Using analysis and prioritization of genetic variants Dr Pillar is able to correlate these changes to specific diseases.

Ofer Isakov

Ofer Isakov
PhD

Bioinformatic architect

> Full Bio

Ofer Isakov serves as the Bioinformatic Pipeline Architect at Variantyx where he develops genetic diagnostics decision-support algorithms based on NGS. He has published many peer-reviewed papers in this field. He received his Ph.D. in Bioinformatics from Tel-Aviv

University and is currently completing his M.D. degree at the Tel Aviv

University Sackler School of Medicine.

> Full bio

Dr. Nir Pillar, M.D., has experience at the Medical Oncology Department at Sheba Medical Center, Tel HaShomer, Israel. His current Ph.D. research focuses on exploring the deep mechanism of genetic based diseases and the combination of DNA and RNA changes that lead to their development. In his role as Variantyx' Clinical Adviser, he plans and implements novel algorithms for understanding the genetic origin of genetic changes that lead to severe phenotypes. Using analysis and prioritization of genetic variants Dr Pillar is able to correlate these changes to specific diseases.

  
  >Full Bio

Ofer Isakov serves as the Bioinformatic Pipeline Architect at Variantyx where he develops genetic diagnostics decision-support algorithms based on NGS. He has published many peer-reviewed papers in this field. He received his Ph.D. in Bioinformatics from Tel-Aviv
University and is currently completing his M.D. degree at the Tel Aviv
University Sackler School of Medicine.

> Full Bio

Dr. Nir Pillar, M.D., has experience at the Medical Oncology Department at Sheba Medical Center, Tel HaShomer, Israel. His current Ph.D. research focuses on exploring the deep mechanism of genetic based diseases and the combination of DNA and RNA changes that lead to their development. In his role as Variantyx' Clinical Adviser, he plans and implements novel algorithms for understanding the genetic origin of genetic changes that lead to severe phenotypes. Using analysis and prioritization of genetic variants Dr Pillar is able to correlate these changes to specific diseases.

> Full Bio

Ofer Isakov serves as the Bioinformatic Pipeline Architect at Variantyx where he develops genetic diagnostics decision-support algorithms based on NGS. He has published many peer-reviewed papers in this field. He received his Ph.D. in Bioinformatics from Tel-Aviv
University and is currently completing his M.D. degree at the Tel Aviv
University Sackler School of Medicine.

Join Us!

We are currently looking for talented and enthusiastic professionals to join the team! If you would like to join us, the following positions are now open for applicants:

  • FN152 - Insurance claim specialist (USA)
  • FN158 - Financial Comptroller (East coast, USA)
  • ET161 - IT specialist (Metro west Massachusetts USA)

Apply by sending your resume to HumanResources@variantyx.com mentioning the position details and detailed contact information.

 

Join Us!

COMPANY: Variantyx, Inc.

TITLE: Chief Information Officer

LOCATION: Framingham, MA

DUTIES: Analyze operations and provide strategic and tactical planning, development, evaluation and coordination of information and technology systems; Delegate responsibilities and facilitate communication between staff, management, vendors and other technology resources within the organization; Oversee the office computer operations, including local area networks and wide-area networks; Manage and oversee multiple information and communications systems and projects, including voice, data, imaging and office automation; Design, implement and evaluate the systems that support end users in the productive use of computer hardware and software; Develop, direct and implement user-training programs, objectives and activities to ensure continuing operations and increase productivity for Variantyx Inc.; Oversee and evaluate system security and backup procedures; and Supervise multiple contractors and build a team of 5 people.

THE POSITION HAS THE FOLLOWING SPECIAL REQUIREMENTS: 10 years of experience in managing Information Technology infrastructure; Proven track record as CIO or related high-level position in a mid-size technology company; Knowledge of and experience in: business process improvement, Salesforce.com, and Visual Force; and Management of IT teams.

MINIMUM EDUCATION AND EXPERIENCE REQUIREMENTS: Bachelor’s degree or the foreign academic equivalent in Industrial Engineering, Information Systems, Computer Science, or a related field plus 10 years of work experience in the job offered or a related occupation.


CONTACT: Variantyx HR, 1671 Worcester Road, Suite 300, Framingham, MA 01701. EOE.

 

Variantyx Inc.

1671 Worcester Rd. Framingham MA 01721 USA

E-mail: info@variantyx.com

Phone: +1.617.209.2090

Fax: 508.879.0002

To connect to our Clinical Coordinators, please fill in the following‏
Comments: